Clinical Trial Update: ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ASTX727 in combination with nivolumab for recurrent or metastatic squamous cell carcinoma of the head and neck has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• nivolumab (nivolumab)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma | Phase 1 | Status: WITHDRAWN